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Background
We are evaluating the immunogenicity and efficacy of a
nanoparticle vaccine (NPV) targeting the tumor marker
human aspartyl (asparaginyl) b-hydroxylase (HAAH).
HAAH is an embryonic protein that is over-expressed
on the surface of cancer cells, is demonstrated to be
responsible for cell proliferation, motility and invasive-
ness, processes which can be inhibited by anti-HAAH
antibodies in vitro. We have developed novel anticancer
NPVs in which portions of the HAAH molecule are
expressed on l-phage (200-300 copies per NPV). These
NPVs are immunogenic; producing high-titer anti-
HAAH polyclonal antibodies in mice despite the fact
that the HAAH protein is highly conserved between
mammalian species. We have further shown that the
NPVs inhibit tumor growth and metastasis and extends
survival in mouse models of liver and breast cancer and
in a rat model of prostate cancer. It is generally under-
stood that for a vaccine to provide lasting protective
immunity it must also elicit strong cellular immune
responses. Here we demonstrate that these HAAH-tar-
geted NPVs can induce antigen specific cytotoxic T cell
(CTL) responses.
Methods
Male Sprague-Dawley rats (N=6/group) were immunized
with 2.5x1011 phage particles displaying either the
N-terminal third (HAAH-1l) or the C-terminal third
(HAAH-3l) of the HAAH protein. Intramuscular (IM)
immunization of the NPV was compared with intrader-
mal (ID) administration using the 3M hMTS device.
Vaccinations occurred on Days 0, 14 and 28 and ani-
mals were sacrificed on Day 35. Spleens were harvested
and CD8+ T cells as well as MHC class II+ antigen pre-
senting cells (APC) were isolated using magnetic
assisted cell sorting (MACS, Milltenyi Biotec). CTL
responses were measured using a fluorescent assay in
which target cells were pre-loaded with 5-(6)-carboxy-
fluorescein diacetate succinimidyl ester (CFSE) and dead
cells were labelled after incubation with effector cells
with 7-amino actinomycin D (7-AAD).
Results
Antigen specific cytotoxic T cell responses were detected
in all vaccinated groups. Specific lysis occurred in HAAH-
loaded vs. not loaded APCs derived from the same ani-
mals. Specific lysis of HAAH-loaded rat prostate cancer
cells (MLLB cells) was also detected. At effector to target
ratios of 25:1, specific lysis ranged from 6-28% (Average =
17%) dependent on the vaccine type (HAAH-1 vs. HAAH-
3) and the route of delivery (IM vs. ID).
Conclusions
We have previously demonstrated that HAAH-targeted
nanoparticle vaccines are immunogenic and protect
against tumor growth and metastasis in vivo and extend
survival. This work demonstrates that these vaccines also
elicit a strong humoral response including development
of HAAH-specific cytotoxic T-lymphocyte responses.
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